Costa Blaise Mathias, Feng Bihua, Tsintsadze Timur S, Morley Richard M, Irvine Mark W, Tsintsadze Vera, Lozovaya Natasha A, Jane David E, Monaghan Daniel T
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198-5800, USA.
J Pharmacol Exp Ther. 2009 Nov;331(2):618-26. doi: 10.1124/jpet.109.156752. Epub 2009 Aug 14.
N-Methyl-d-aspartate (NMDA) receptor antagonists that are highly selective for specific NMDA receptor 2 (NR2) subunits have several potential therapeutic applications; however, to date, only NR2B-selective antagonists have been described. Whereas most glutamate binding site antagonists display a common pattern of NR2 selectivity, NR2A > NR2B > NR2C > NR2D (high to low affinity), (2S*,3R*)-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid (PPDA) has a low selectivity for NR2C- and NR2D-containing NMDA receptors. A series of PPDA derivatives were synthesized and then tested at recombinant NMDA receptors expressed in Xenopus laevis oocytes. In addition, the optical isomers of PPDA were resolved; the (-) isomer displayed a 50- to 80-fold greater potency than the (+) isomer. Replacement of the phenanthrene moiety of PPDA with naphthalene or anthracene did not improve selectivity. However, phenylazobenzoyl (UBP125) or phenylethynylbenzoyl (UBP128) substitution significantly improved selectivity for NR2B-, NR2C-, and NR2D-containing receptors over NR2A-containing NMDA receptors. Phenanthrene attachment at the 3 position [(2R*,3S*)-1-(phenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid (UBP141); (2R*,3S*)-1-(9-bromophenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid (UBP145); (2R*,3S*)-1-(9-chlorophenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid (UBP160); and (2R*,3S*)-1-(9-iodophenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid (UBP161)] displayed improved NR2D selectivity. UBP141 and its 9-brominated homolog (UBP145) both display a 7- to 10- fold selectivity for NR2D-containing receptors over NR2B- or NR2A-containing receptors. Schild analysis indicates that these two compounds are competitive glutamate binding site antagonists. Consistent with a physiological role for NR2D-containing receptors in the hippocampus, UBP141 (5 muM) displayed greater selectivity than PPDA for inhibiting the slow-decaying component of the NMDA receptor-mediated CA3-CA1 synaptic response in rat hippocampal slices. UBP125, UBP128, UBP141, and UBP145 may be useful tools for determining the function of NMDA receptor subtypes.
对特定N-甲基-D-天冬氨酸(NMDA)受体2(NR2)亚基具有高度选择性的NMDA受体拮抗剂有多种潜在治疗应用;然而,迄今为止,仅描述了NR2B选择性拮抗剂。大多数谷氨酸结合位点拮抗剂呈现出常见的NR2选择性模式,即NR2A>NR2B>NR2C>NR2D(亲和力从高到低),而(2S*,3R*)-1-(菲-2-羰基)哌嗪-2,3-二羧酸(PPDA)对含NR2C和NR2D的NMDA受体选择性较低。合成了一系列PPDA衍生物,然后在非洲爪蟾卵母细胞中表达的重组NMDA受体上进行测试。此外,拆分了PPDA的旋光异构体;(-)异构体的效力比(+)异构体高50至80倍。用萘或蒽取代PPDA的菲部分并未提高选择性。然而,苯偶氮苯甲酰基(UBP125)或苯乙炔基苯甲酰基(UBP128)取代显著提高了对含NR2B-、NR2C-和NR2D的受体相对于含NR2A的NMDA受体的选择性。在3位连接菲基[(2R*,3S*)-1-(菲-3-羰基)哌嗪-2,3-二羧酸(UBP141);(2R*,3S*)-1-(9-溴菲-3-羰基)哌嗪-2,3-二羧酸(UBP145);(2R*,3S*)-1-(9-氯菲-3-羰基)哌嗪-2,3-二羧酸(UBP160);和(2R*,3S*)-1-(9-碘菲-3-羰基)哌嗪-2,3-二羧酸(UBP161)]显示出对NR2D的选择性提高。UBP141及其9-溴化同系物(UBP145)对含NR2D的受体相对于含NR2B或NR2A的受体均表现出7至10倍的选择性。Schild分析表明这两种化合物是竞争性谷氨酸结合位点拮抗剂。与含NR2D的受体在海马体中的生理作用一致,UBP141(5μM)在抑制大鼠海马体切片中NMDA受体介导的CA3-CA1突触反应的慢衰减成分方面比PPDA表现出更高的选择性。UBP125、UBP128、UBP141和UBP145可能是确定NMDA受体亚型功能的有用工具。